Titre du document / Document title

Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder : An empirical evaluation of olanzapine, risperidone, and quetiapine

Auteur(s) / Author(s)

BYERLY Matthew J. ⁽¹⁾ ; NAKONEZNY Paul A. ⁽²⁾ ; MAGOUIRK BETTCHER Brianne ⁽¹⁾ ; CARMODY Thomas ⁽²⁾ ; FISHER Robert ⁽¹⁾ ; RUSH A. John ⁽³⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ The University of Texas Southwestern Medical Center, Department of Psychiatry, 6363 Forest Park Rd, Suite 651, Dallas, TX 75235-8828, ETATS-UNIS
⁽²⁾ Department of Clinical Sciences, Division of Biostatistics, The University of Texas Southwestern Medical Center, 6363 Forest Park Rd, Suite 651, Dallas, TX 75235-8828, ETATS-UNIS
⁽³⁾ Department of Clinical Sciences and Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235-9066, ETATS-UNIS

Résumé / Abstract

Objective: Evaluate sexual dysfunction, as measured by the Arizona Sexual Experience Scale (ASEX), in olanzapine-, quetiapine-, and risperidone-treated outpatients with schizophrenia or schizoaffective disorder. Method: The sexual functioning of 238 outpatients (age≥18 years) with diagnoses of schizophrenia or schizoaffective disorder who took quetiapine (n=57), olanzapine (n=94), or risperidone (n=87) was evaluated with a one-time rating of the ASEX. The dose range for each treatment group was 5 to 40 mg/day (M= 16.6 mg/day, SD=7.4) for olanzapine; 1 to 8 mg/day (M=3.9 mg/ day, SD=1.6) for risperidone; and 50 to 900 mg/day (M=376.8 mg/day, SD=213.4) for quetiapine. Antipsychotic group designation was based on medication treatment at study entry (i.e., non-random assignment). Participant characteristics were collected to test for treatment group differences and for potential associations with severity of sexual dysfunction. The primary data analysis was a mixed linear model analysis of covariance with age, gender, and presence/absence of antidepressant known to cause sexual dysfunction included as covariates. Results: There was a significant treatment effect on severity of sexual dysfunction, as measured by ASEX total scores (p=.04). The adjusted average ASEX total scores were lower in the quetiapine (M=17.80) than in the risperidone (M=19.69) or olanzapine (M=20.34) groups. Individual comparisons of the treatments on adjusted average ASEX total scores indicated a significant difference between olanzapine and quetiapine (p =.04), but no difference between risperidone and quetiapine (p=.17) or olanzapine and risperidone (p=.76). Conclusions: Quetiapine was associated with less severe sexual dysfunction than olanzapine and risperidone (albeit the effect between risperidone and quetiapine was not statistically significant). Olanzapine and risperidone were associated with a comparable degree of sexual dysfunction. Patients in all three treatment groups, nonetheless, experienced a moderately high degree of sexual dysfunction. Because the patients were not randomized, conclusions must be interpreted within the context of the quasi-experimental design.

Revue / Journal Title

Schizophrenia research   ISSN 0920-9964 

Source / Source

2006, vol. 86, n^o1-3, pp. 244-250 [7 page(s) (article)] (25 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier Science, Amsterdam, PAYS-BAS  (1988) (Revue)

Mots-clés anglais / English Keywords

Dibenzothiazepine derivatives ; Thienobenzodiazepine derivatives ; Serotonine receptor ; D2 Dopamine receptor ; Serotonin antagonist ; Dopamine antagonist ; Tranquillizer ; Hypnotic ; Atypical antipsychotic ; Human ; Quetiapine ; Risperidone ; Olanzapine ; Evaluation ; Schizoaffective psychosis ; Schizophrenia ; Psychotropic ; Treatment ; Chemotherapy ; Neuroleptic ; Sexual dysfunction ;

Mots-clés français / French Keywords

Dibenzothiazépine dérivé ; Thiénobenzodiazépine dérivé ; Récepteur sérotoninergique ; Récepteur dopaminergique D2 ; Antagoniste sérotonine ; Antagoniste dopamine ; Tranquillisant ; Hypnotique ; Antipsychotique atypique ; Homme ; Quétiapine ; Rispéridone ; Olanzapine ; Evaluation ; Psychose schizoaffective ; Schizophrénie ; Psychotrope ; Traitement ; Chimiothérapie ; Neuroleptique ; Dysfonctionnement sexuel ;

Mots-clés espagnols / Spanish Keywords

Dibenzotiazepina derivado ; Thienobenzodiazepina derivado ; Receptor serotoninérgico ; Receptor dopaminérgico D2 ; Antagonista serotonina ; Antagonista dopamina ; Tranquilizante ; Hipnótico ; Antipsicótico atípico ; Hombre ; Quetiapina ; Risperidona ; Olanzapina ; Evaluación ; Psicosis esquizoafectiva ; Esquizofrenia ; Psicotropo ; Tratamiento ; Quimioterapia ; Neuroléptico ; Disfunción sexual ;

Mots-clés d'auteur / Author Keywords

Schizophrenia ; Sexual dysfunction ; Antipsychotics ;

Localisation / Location

INIST-CNRS, Cote INIST : 21734, 35400014225065.0310